BeOne Medicines Presents New Data on TEVIMBRA in Lung Cancer at ESMO 2025
New data from two pivotal TEVIMBRA studies – RATIONALE-307 and -312 – reinforce the PD-1 inhibitor's proven clinical benefit in both NSCLC and ES-SCLC Early data from investigational HPK1 inhibitor BGB-26808, in combination with TEVIMBRA, show promise in adva
(Financial Post, 2025-10-20T10:10:40Z)